Predictors of response to tumor necrosis factor-α blockers in ankylosing spondylitis

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1637-1640

  Burgos Vargas, Rubén ^a,b   Rojas Serrano, Jorge ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; GAMMA INTERFERON; HLA B27 ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA BLOCKING AGENT; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BACKACHE; BIOLOGICAL THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; EVIDENCE BASED MEDICINE; GENETIC POLYMORPHISM; HEREDITY; HUMAN; INTERFERON PRODUCTION; PAIN ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RADIOGRAPHY; TREATMENT FAILURE;

BIOLOGICAL PRODUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944471265     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Davis JC, van der Heijde D, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.
2. Braun J, Pham T, Sieper J, et al, and the ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
3. Maksymowych WC, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS, the Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association Consensus for the use of anti-tumor necrosis factor directed therapies in the treatment of the Spondyloarthritis. J Rheumatol 2003;30:1356-63.
4. Keat A, Barkham N, Bhalla A, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology Oxford 2005;44:939-47.
5. Pham T, Landewe R, Dougados M, et al. ISASS: International Start TNF-Blocker Study in Ankylosing Spondylitis [abstract]. Arthritis Rheum 2004;50 Suppl:S216.
6. Landewe R, Rump B, van der Heijde D, van der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis 2004;63:530-4.
7. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol 1994;21:2286-91.
8. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
9. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
10. van Tubergen A, van der Heijde D, Anderson J, et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 2003;62:215-21.
11. Stone MA, Inman RD, Wright JG, Maetzel A. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004;51:316-20.
12. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
13. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
14. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
15. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
16. Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004;63:84-7.
17. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Kiel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
18. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-α antibody infliximab. Ann Rheum Dis 2005 Mar 18; e-pub ahead of print.
19. Davis JC Jr, van der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
20. Liang KY, Zeger JL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:12-22.
21. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Scientific; 2002:440-3.
22. Hider SL, Buckley C, Silman AJ, Symmons DP, Bruce IN. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol 2005;32:11-6.
23. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum 2000;43:22-9.
24. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82.
25. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6.
26. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology Oxford 2005;44:547-52.
27. Schotte H, Schluter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:575-81.